a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. ACL, aclidinium; Crl, credible interval; FEV1, forced expiratory volume in 1 second; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol. a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. ACL, aclidinium; Crl, credible interval; FEV1, forced expiratory volume in 1 second; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; SAL, salmeterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol. a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. CrI, credible interval; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; SGRQ, St George's Respiratory Questionnaire; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.
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Supplementary a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. ACL, aclidinium; Crl, credible interval; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; SAL, salmeterol; SGRQ, St George's Respiratory Questionnaire; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.
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Supplementary a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. ACL, aclidinium; Crl, credible interval; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol. a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. CFB, change from baseline; Crl, credible interval; FEV1, forced expiratory volume in 1 second; FOR, formoterol; GLY, glycopyrronium; ICS, inhaled corticosteroid; IND, indacaterol; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol. a Where the probability of improved outcomes using therapy A vs therapy B is X%, the probability of improved outcomes using therapy B vs therapy A is (100-X)%. CFB, change from baseline; Crl, credible interval; FEV1, forced expiratory volume in 1 second; FOR, formoterol; GLY, glycopyrronium; IND, indacaterol; OLO, olodaterol; TIO, tiotropium; UMEC, umeclidinium; VI, vilanterol.
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